CARDIAC MARKERS IN THE BLOOD OF RATS EXPOSED TO FREE AND BOUND DOXORUBICIN

Аннотация

The anthracycline antibiotic doxorubicin (DOX) is widely used in clinical practice for the treatment of cancer; however, its high cardiotoxicity limits its use. The development of targeted delivery systems for the cytostatic agent to the tumor site has significantly reduced DOX toxicity. Research in this area has also been conducted at the Institute of Bioorganic Chemistry of the Academy of Sciences of the Republic of Uzbekistan, where various DOX derivatives have been obtained. Comprehensive studies are currently underway on the promising polysaccharide conjugated drug PGA-DOX. To assess the cardiotoxic effect of various drugs, levels of various cardiac markers are determined.